Dual inhibitor trypsin antibodies and uses thereof
WO2026085370A3PCT designated stage Publication Date: 2026-05-28TRIVENI BIO INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/051328
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-07-01
- Filing Date
- 2025-10-16
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Current treatment options for pancreatitis, including hereditary, acute, and chronic forms, are limited, and there is a need for effective inhibitors of trypsin 1 and trypsin 2 to manage pancreatitis-related conditions.
Method used
Development of dual inhibitor antibodies that specifically bind to both trypsin 1 and trypsin 2 with high affinity and specificity, utilizing specific CDR sequences and modified heavy chain constant regions to reduce effector function and extend serum half-life, thereby inhibiting trypsin activity.
Benefits of technology
The dual inhibitor antibodies effectively target and inhibit trypsin activity, reducing pancreas tissue damage, edema, and cell death, providing a potential treatment for hereditary, acute, and chronic pancreatitis.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025051328_28052026_PF_FP_ABST
Abstract
Aspects of the application provide dual inhibitor anti-trypsin 1 / trypsin 2 antibodies and methods of using the same for treating pancreatitis. Other aspects of the application provide engineered non-human organisms encoding a human trypsin 1 protein.
Need to check novelty before this filing date? Find Prior Art